Clinical Trial ResultsTSC-100/101 continued to strongly favor the treatment arm, with only 8% of patients in the treatment arm having relapsed compared to 33% in the control arm.
Financial StabilityThe company ended with $252M in cash, supporting operations into 1Q:27.
Regulatory SupportThe proposed primary endpoint for the trial is relapse-free survival, for which the FDA is supportive.